Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Head and Neck Neoplasms 2Stomatitis 1Mucositis 1Abnormalities, Radiation-Induced 1

Interventions

Radiotherapy 6Fibroblast Growth Factor 7 4Injections 3Drug Therapy 3Cisplatin 3Water 2Propolis 2Mouthwashes 2Morphine 2Methotrexate 2Melphalan 2Low-Level Light Therapy 2Interleukin 1 Receptor Antagonist Protein 2Gabapentin 2Cryotherapy 2peppermint oil 1pegaspargase 1oxycodone-acetaminophen 1nelarabine 1kang-lai-te 1glucarpidase 1fludarabine phosphate 1fish oil triglycerides 1cyclohexaneacetic acid 1calcium phosphate 1brilacidin 1anise oil 1amlexanox 1aluminum hydroxide, magnesium hydroxide, drug combination 1acetaminophen, hydrocodone drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mucositis × oxycodone-acetaminophen × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡